Stanford, CALIFORNIA8 Active Studies

Rheumatoid Arthritis Clinical Trials in Stanford, CALIFORNIA

Find 8 actively recruiting rheumatoid arthritis clinical trials in Stanford, CALIFORNIA. Connect with local research sites and explore new treatment options.

8
Active Trials
7
Sponsors
2,482
Enrolling

Recruiting Rheumatoid Arthritis Studies in Stanford

RecruitingStanford, CALIFORNIANCT06109779

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection ...

750 participants
AstraZeneca
View Study Details
RecruitingStanford, CALIFORNIANCT06563895

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different orga...

582 participants
Eidos Therapeutics, a BridgeBio company
View Study Details
RecruitingStanford, CALIFORNIANCT06830798

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are ...

450 participants
Alexion Pharmaceuticals, Inc.
View Study Details
RecruitingStanford, CALIFORNIANCT05947071

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV). Rec...

312 participants
National Institute of Allergy and Infectious Diseases (NIAID)
View Study Details
RecruitingStanford, CALIFORNIANCT06082037

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both...

180 participants
Sanofi
View Study Details
RecruitingStanford, CALIFORNIANCT06388564

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in par...

120 participants
Incyte Corporation
View Study Details
RecruitingStanford, CALIFORNIANCT03949855

Belimumab With Rituximab for Primary Membranous Nephropathy

The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituxim...

58 participants
National Institute of Allergy and Infectious Diseases (NIAID)
View Study Details
RecruitingStanford, CALIFORNIANCT06954805

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in participants who have high-ris...

30 participants
Jennifer Amengual
View Study Details

About Rheumatoid Arthritis Clinical Trials in Stanford

Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1.3 million Americans, where the immune system mistakenly attacks joint linings, causing painful swelling, bone erosion, and joint deformity. Early diagnosis and treatment are critical to prevent irreversible damage. Current standard treatments include methotrexate and other DMARDs, TNF inhibitors (etanercept, infliximab), IL-6 inhibitors (tocilizumab), T-cell costimulation modulators (abatacept), and JAK inhibitors (tofacitinib, baricitinib). Clinical trials are now exploring next-generation targeted therapies, dual-pathway inhibitors, and treatment strategies aimed at achieving sustained remission rather than just symptom control. Patients with inadequate response to conventional DMARDs or biologics are commonly eligible for enrollment.

There are currently 8 rheumatoid arthritis clinical trials recruiting participants in Stanford, CALIFORNIA. These studies are seeking a combined 2,482 participants. Research is being sponsored by AstraZeneca, Eidos Therapeutics, a BridgeBio company, Alexion Pharmaceuticals, Inc. and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Rheumatoid Arthritis Clinical Trials in Stanford — FAQ

Are there rheumatoid arthritis clinical trials in Stanford?

Yes, there are 8 rheumatoid arthritis clinical trials currently recruiting in Stanford, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Stanford?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Stanford research site will contact you about next steps.

Are clinical trials in Stanford free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Stanford studies also compensate for your time and travel.

What rheumatoid arthritis treatments are being tested?

The 8 active trials in Stanford are testing new therapies including novel drugs, biologics, and treatment approaches for rheumatoid arthritis.

Data updated March 2, 2026 from ClinicalTrials.gov